Chiesi Farmaceutici
↗Parma, Italy
Chiesi Farmaceutici S.p.A. is a global Italian pharmaceutical company headquartered in Parma, Italy, specializing in respiratory diseases, rare and ultra-rare diseases, neonatology, and specialty care. Founded in 1935 by Giacomo Chiesi, the company has grown into an international player with operations in over 100 countries and nearly 6,500 employees worldwide. The company is characterized by its family-controlled ownership structure, managed through Valline S.r.l., a private holding company of the Chiesi family. Chiesi operates through three primary business franchises: Air (respiratory), Rare (rare and ultra-rare diseases), and Care (neonatology and specialty care). With significant operations across Europe, North America, and Asia-Pacific, Chiesi combines traditional pharmaceutical expertise with growing investments in biologics and advanced therapies.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Respiratory therapeutics, Rare diseases, Neonatology
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.2B-$3.5B
Founded:1935
Ownership:private
Status:operating
FUNDING
Stage:Mature/Private
Total Raised:$758M
Investors:Valline S.r.l. (Family holding company)
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 2b (OHB-607 for BPD)
Modalities:Small molecule, Biologics/Proteins, Topical formulations, Enzyme replacement therapy, RNA-targeted approaches, Metered dose inhalers, Dry powder inhalers, Gene modulation
Trial Phases:Phase 2: 2
FDA Approvals:3
EMA Approvals:4
CORPORATE STRUCTURE
Subsidiaries:Chiesi Global Rare Diseases (formerly Amryt Pharma), Chiesi USA, Inc., Chiesi Limited (UK), Chiesi France, Chiesi Sweden, Chiesi Brazil, Chiesi China, Chiesi Canada
Key Partnerships:Oak Hill Bio: License and Development Agreement for OHB-607 (IGF-1 therapy for bronchopulmonary dysplasia prevention), Protalix BioTherapeutics: Global development and commercialization of Elfabrio® (pegunigalsidase alfa-iwxj) for Fabry disease, Moderna: Collaboration to discover and develop mRNA therapeutics for Pulmonary Arterial Hypertension (PAH), Serna Bio: Strategic collaboration to discover and develop RNA-targeted small molecules for respiratory diseases (announced November 2025), Aliada Therapeutics: Exclusive license agreement (announced November 12, 2025), Samay: Collaboration to develop novel algorithms for early detection of small airway disease (SAD), Charles River Labs: Extended respiratory drug discovery partnership
COMPETITION
Position:Leader
Competitors:Vertex Pharmaceuticals (cystic fibrosis, rare diseases), CSL Behring (biopharmaceuticals, specialty therapies), AstraZeneca (respiratory, inhalers), GlaxoSmithKline (respiratory, COPD/asthma), Boehringer Ingelheim (respiratory), Cipla (emerging markets focus), EMS Pharma (respiratory, specialty medicines)
LEADERSHIP
Key Executives:
Giuseppe Accogli - Chief Executive Officer (CEO)
Alberto Chiesi - President
Giacomo Chiesi - Executive Vice President, Chiesi Global Rare Diseases; Board Member
Marco Vecchia - Head of Legal and Corporate Affairs
Laura Vergani - Senior Vice President, Global Communications & Public Affairs
Jon Zwinski - Senior Vice President, Region USA
Scientific Founders:Giacomo Chiesi (founder, 1935)
Board Members:Alberto Chiesi (President), Giuseppe Accogli (CEO), Giacomo Chiesi (Board Member), Roch Doliveux (Independent Non-Executive Director, appointed 2025), Paolo Pucci (Independent Non-Executive Director, appointed 2025), Daphne Quimi (Independent Non-Executive Director, appointed 2025)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Chiesi Farmaceutici. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.